| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 2mg | |||
| Other Sizes |
| Targets |
Sofosbuvir impurity N is a diastereomer of sofosbuvir, which targets the HCV NS5B RNA-dependent RNA polymerase. Sofosbuvir is a nucleotide analog prodrug that, after intracellular metabolism to the active triphosphate form, acts as a chain terminator during HCV RNA replication. The impurity itself may not have significant biological activity but is used as a reference standard for analytical purposes. Its primary relevance is in pharmaceutical quality control and analytical chemistry to monitor the purity of sofosbuvir preparations.
|
|---|---|
| ln Vitro |
Sofosbuvir impurity N itself is not evaluated for pharmacological activity, as it is used as a reference standard for analytical purposes. Sofosbuvir, the parent drug, is an inhibitor of HCV RNA replication with potent anti-hepatitis C virus activity. The impurity is a related substance that may be present in sofosbuvir preparations. Its presence and quantity are monitored to ensure the quality and purity of pharmaceutical preparations. The compound is used in analytical methods such as HPLC to identify and quantify impurities. Its activity is not characterized in terms of pharmacological effects but rather in terms of analytical properties such as retention time and spectral characteristics.
|
| ln Vivo |
In vivo activity of Sofosbuvir impurity N is not applicable, as the compound is used as a reference standard for analytical purposes rather than as a therapeutic agent. Sofosbuvir, the parent drug, is used clinically for the treatment of chronic hepatitis C virus infection. The impurity itself is not administered therapeutically and is not intended for in vivo studies. Its primary use is in pharmaceutical quality control and analytical chemistry.
|
| Enzyme Assay |
In vitro assays for Sofosbuvir impurity N are primarily analytical rather than pharmacological. High-performance liquid chromatography (HPLC) and mass spectrometry are used to identify and quantify the impurity in sofosbuvir preparations. The compound's retention time and spectral characteristics are compared to reference standards to confirm its identity. Purity analysis is performed using HPLC with UV detection. The compound's molecular weight (501.40 g/mol) and formula (C20H25FN3O9P) are confirmed by mass spectrometry. Stability studies may be performed to assess the compound's degradation under various conditions. The impurity is used as a reference standard in pharmaceutical quality control laboratories.
|
| Cell Assay |
In vitro cellular assays are not applicable for Sofosbuvir impurity N, as the compound is used as a reference standard for analytical purposes rather than for biological activity studies. The compound is not evaluated in cell-based assays for pharmacological activity. Its primary use is in pharmaceutical quality control to ensure the purity of sofosbuvir preparations. If cellular assays were to be performed, appropriate cell lines expressing HCV replicons could be used to assess any potential antiviral activity of the impurity. However, such studies are not typically conducted for impurities. The compound is intended for research use as an analytical standard.
|
| Animal Protocol |
In vivo animal studies are not applicable for Sofosbuvir impurity N, as the compound is used as a reference standard for analytical purposes rather than as a therapeutic agent. The impurity is not administered to animals for efficacy or safety studies. Sofosbuvir, the parent drug, has been studied in animal models for its antiviral activity. The impurity itself is not evaluated in animal models. Its primary use is in pharmaceutical quality control and analytical chemistry.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Sofosbuvir impurity N are not relevant, as the compound is used as a reference standard for analytical purposes rather than as a therapeutic agent. The compound has a molecular formula of C20H25FN3O9P and a molecular weight of 501.40 g/mol. Its chemical name is methyl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate. Comprehensive pharmacokinetic parameters are not relevant for an analytical standard.
|
| Toxicity/Toxicokinetics |
Sofosbuvir impurity N is intended for laboratory research use only and has not undergone toxicology testing for therapeutic applications. As an impurity of a pharmaceutical compound, its toxicity profile would be relevant for quality control purposes to ensure that impurity levels are within acceptable limits. The compound is used as a reference standard for analytical purposes. Standard handling precautions for chemical research compounds should be followed. Comprehensive toxicological characterization has not been reported, as the compound is not intended for human use.
|
| Additional Infomation |
Sofosbuvir impurity N is a diastereoisomer and impurity of sofosbuvir, an inhibitor of HCV RNA replication. It is formed as a process-related impurity during synthesis or as a degradation product under specific stress conditions. The compound has a molecular formula of C20H25FN3O9P and a molecular weight of 501.40 g/mol. Sofosbuvir impurity N is used as a reference standard for analytical and quality control purposes. The compound has not entered clinical trials and is available for research purposes only.
|
| Molecular Formula |
C20H25FN3O9P
|
|---|---|
| Molecular Weight |
501.399369955063
|
| Exact Mass |
501.131
|
| CAS # |
1394157-34-6
|
| PubChem CID |
45268391
|
| Appearance |
White to off-white solid powder
|
| LogP |
0.2
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
34
|
| Complexity |
868
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C[C@@H](C(=O)OC)NP(=O)(OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3
|
| InChi Key |
SASYBZIIPQSWBV-HJDNSYGMSA-N
|
| InChi Code |
InChI=1S/C20H25FN3O9P/c1-12(17(27)30-3)23-34(29,33-13-7-5-4-6-8-13)31-11-14-16(26)20(2,21)18(32-14)24-10-9-15(25)22-19(24)28/h4-10,12,14,16,18,26H,11H2,1-3H3,(H,23,29)(H,22,25,28)/t12-,14+,16+,18+,20+,34?/m0/s1
|
| Chemical Name |
methyl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~199.44 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9944 mL | 9.9721 mL | 19.9442 mL | |
| 5 mM | 0.3989 mL | 1.9944 mL | 3.9888 mL | |
| 10 mM | 0.1994 mL | 0.9972 mL | 1.9944 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
